PHENIRAMINE

Fetal Risk Summary

The Collaborative Perinatal Project monitored 50,282 mother-child pairs, 831 of whom were exposed to pheniramine during the 1st trimester (1, pp. 322–334). A possible relationship between this use and respiratory malformations and eye/ear defects was found, but the statistical significance of these findings is unknown. Independent confirmation is required to determine the actual risk. For use anytime during pregnancy, 2,442 exposures were recorded (1, pp. 436–437). No evidence was found in this group to suggest a relationship to congenital anomalies.

An association between exposure during the last 2 weeks of pregnancy to antihistamines in general and retrolental fibroplasia in premature infants has been reported. See Brompheniramine for details.

Breast Feeding Summary

No data are available.

Reference